Ironwood Pharmaceuticals develops and markets gastrointestinal products such as LINZESS for the treatment of irritable bowel syndrome and chronic constipation. The company is also developing GC-C agonists for the treatment of pain conditions and immune nanoparticles for cholangitis treatment. Ironwood has partnerships with AbbVie, AstraZeneca, and Astellas Pharma for the development and marketing of their products.